FLT3 and acute myeloid leukemia: Cobimetinib sensitive AML cells also had elevated FLT3 levels (32 versus 16 ng/μg) indicating that NK AML cells with elevated FLT3 levels may be particularly susceptible to the combined treatment with idasanutlin and cobimetinib.